Brodalumab in psoriasis: evidence to date and clinical potential

Drugs in Context

article

Amy C Foulkes¹  Richard B Warren¹ 

[1] The Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester Biomedical Research Centre

关键词: immune-mediated inflammatory disease;    psoriasis;    psoriatic arthritis.;   

DOI  :  10.7573/dic.212570

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

Brodalumab is a recombinant, fully human monoclonalantibody (IgG2) which binds with high affinity to the interleukin(IL) 17 receptor A (IL17R). Brodalumab is now licensed andapproved for the treatment of moderate-to-severe chronicplaque psoriasis in North America and Europe. As the thirdto market in the class of agents targeting IL-17, we review itsplace in the expanding armamentarium of cytokine-directedtherapies for patients with severe psoriasis. Brodalumab is ahighly efficacious therapy for psoriasis, whose mechanism ofaction is separate from other treatments targeting IL-17. Its useis associated with rapid control of the disease. We suggest thatbrodalumab is likely to be considered in those patients requiringrapid control of disease, where there is no known history ofdepression or suicidal ideation.

【 授权许可】

CC BY-NC-ND